Capital Research Global Investors decreased its stake in Netflix Inc (NFLX) by 3.58% based on its latest 2017Q3 regulatory filing with the SEC. Capital Research Global Investors sold 1.74 million shares as the company’s stock rose 10.41% with the market. The institutional investor held 46.91 million shares of the consumer services company at the end of 2017Q3, valued at $8.51B, down from 48.65M at the end of the previous reported quarter. Capital Research Global Investors who had been investing in Netflix Inc for a number of months, seems to be less bullish one the $95.40 billion market cap company. The stock increased 0.06% or $0.13 during the last trading session, reaching $220.46. About 10.55M shares traded or 70.74% up from the average. Netflix, Inc. (NASDAQ:NFLX) has risen 75.34% since January 20, 2017 and is uptrending. It has outperformed by 58.64% the S&P500.
Dearborn Partners Llc decreased its stake in Gilead Sciences Incorporated (GILD) by 5.67% based on its latest 2017Q3 regulatory filing with the SEC. Dearborn Partners Llc sold 12,321 shares as the company’s stock declined 8.05% while stock markets rallied. The institutional investor held 204,906 shares of the health care company at the end of 2017Q3, valued at $16.60 million, down from 217,227 at the end of the previous reported quarter. Dearborn Partners Llc who had been investing in Gilead Sciences Incorporated for a number of months, seems to be less bullish one the $105.78B market cap company. The stock decreased 0.23% or $0.19 during the last trading session, reaching $80.98. About 7.92 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 20, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.
Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. They expect $1.67 earnings per share, down 36.74% or $0.97 from last year’s $2.64 per share. GILD’s profit will be $2.18 billion for 12.12 P/E if the $1.67 EPS becomes a reality. After $2.23 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth.
Since August 1, 2017, it had 0 insider purchases, and 12 insider sales for $43.50 million activity. The insider Alton Gregg H sold $1.11M. Shares for $4.99 million were sold by Meyers James R. 51,820 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $4.40 million were sold by Washington Robin L.
Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It is positive, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Dreman Value Mgmt L L C owns 10,932 shares for 0.49% of their portfolio. Next Financial Group holds 6,092 shares. Mcclain Value Mngmt Ltd Company stated it has 39,806 shares or 4.54% of all its holdings. Ashfield Capital Prtn Ltd Liability owns 0.03% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 2,820 shares. C Worldwide Group A S reported 4.96% stake. Plancorp invested in 0.4% or 16,872 shares. Parnassus Investments Ca holds 6.21% in Gilead Sciences, Inc. (NASDAQ:GILD) or 18.70 million shares. Payden Rygel has 2.02% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Cedar Hill Associates Ltd Co, a Illinois-based fund reported 3,331 shares. Nomura Asset Mngmt Co Ltd reported 821,060 shares. Caprock Group Incorporated Inc reported 5,038 shares. Meridian Investment Counsel Incorporated holds 0.92% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 21,847 shares. Palisade Cap Ltd Company Nj accumulated 8,235 shares or 0.02% of the stock. Platinum Invest Mngmt Ltd holds 2.90M shares. Commonwealth Bank & Trust Of Australia holds 0.22% or 284,030 shares.
Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences had 112 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, November 8 by Mizuho. The firm has “Buy” rating by Citigroup given on Thursday, February 25. The firm earned “Buy” rating on Monday, November 14 by Stifel Nicolaus. RBC Capital Markets maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Monday, October 3. RBC Capital Markets has “Outperform” rating and $95 target. The stock has “Outperform” rating by BMO Capital Markets on Friday, October 27. As per Wednesday, February 3, the company rating was maintained by Credit Suisse. Maxim Group maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, May 30 with “Hold” rating. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, July 25. Morgan Stanley maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Friday, October 6. Morgan Stanley has “Equal-Weight” rating and $83 target. The rating was reinitiated by Jefferies on Tuesday, July 11 with “Hold”.
Capital Research Global Investors, which manages about $331.24B US Long portfolio, upped its stake in Micron Technology Inc (NASDAQ:MU) by 5.14 million shares to 44.93 million shares, valued at $1.77B in 2017Q3, according to the filing. It also increased its holding in Signet Jewelers Ltd (NYSE:SIG) by 800,465 shares in the quarter, for a total of 6.18 million shares, and has risen its stake in Vale Sa On Adr (NYSE:VALE).
Investors sentiment decreased to 1.12 in Q3 2017. Its down 0.10, from 1.22 in 2017Q2. It is negative, as 56 investors sold NFLX shares while 255 reduced holdings. 115 funds opened positions while 233 raised stakes. 356.10 million shares or 3.23% more from 344.96 million shares in 2017Q2 were reported. First Manhattan reported 0% stake. Liberty Mutual Gru Asset Management reported 20,162 shares. Private Wealth Advisors stated it has 10,541 shares or 0.78% of all its holdings. Ctc Lc holds 0% or 27,445 shares in its portfolio. Northrock Lc owns 1,326 shares for 0.09% of their portfolio. Trexquant Inv LP invested in 8,225 shares or 0.38% of the stock. Counselors owns 4,711 shares for 0.04% of their portfolio. Clearbridge Invests Lc has invested 0% in Netflix, Inc. (NASDAQ:NFLX). Murphy Mgmt stated it has 0.11% of its portfolio in Netflix, Inc. (NASDAQ:NFLX). The Maryland-based Chevy Chase Trust Inc has invested 0.31% in Netflix, Inc. (NASDAQ:NFLX). Jump Trading Limited Liability Com owns 8,801 shares or 0.29% of their US portfolio. 847,047 are held by Zevenbergen Cap Invests Lc. London Comm Of Virginia reported 0% in Netflix, Inc. (NASDAQ:NFLX). 181,716 are held by Churchill Mgmt Corp. Bridgecreek Investment Management Limited Liability Corp owns 41,630 shares.
Among 55 analysts covering Netflix (NASDAQ:NFLX), 39 have Buy rating, 2 Sell and 14 Hold. Therefore 71% are positive. Netflix had 212 analyst reports since August 4, 2015 according to SRatingsIntel. As per Tuesday, February 2, the company rating was upgraded by Piper Jaffray. The company was downgraded on Tuesday, September 13 by Macquarie Research. The stock has “Buy” rating by Brean Capital on Monday, November 21. The firm has “Buy” rating by Wells Fargo given on Monday, January 8. Canaccord Genuity initiated it with “Buy” rating and $120 target in Friday, July 1 report. The stock has “Buy” rating by Nomura on Monday, July 17. BNP Paribas upgraded Netflix, Inc. (NASDAQ:NFLX) on Friday, August 28 to “Neutral” rating. Loop Capital maintained it with “Buy” rating and $242 target in Tuesday, October 17 report. The stock of Netflix, Inc. (NASDAQ:NFLX) has “Hold” rating given on Tuesday, September 1 by Vetr. The firm earned “Buy” rating on Friday, October 13 by Goldman Sachs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.